Skip to content

9 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX

The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.

B. Huffman, Haeseong Park, N. Jackson et al. · 0 citations
Sep 2026

Abstract B096: Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer

It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.

Sarah Kang, M. Parikh, Leontios Pappas et al. · 0 citations
Sep 2026

Abstract PR008: EMT-associated focal adhesion signaling mediates resistance to RAS inhibition

Direct inhibition of oncogenic RAS has emerged as a clinically active therapeutic strategy for RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). However, resistance is likely to limit the durability of therapeutic response, motivating combination strategies that target adaptive survival mechani...

Joshua H. Choe, Kyle J. Seamon, Julien Dilly et al. · 0 citations
Open access Sep 2026

CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...

Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al. · 0 citations
Sep 2026

Abstract PR006: A time-to-event model for pancreatic cancer risk prediction across multiple future intervals using longitudinal structured electronic health records

This approach may serve as a first-stage, low-cost clinical stratification tool to identify high-risk individuals before more resource-intensive downstream screening such as pancreas-directed imaging as well as promising generalizability to an independent healthcare system.

Ji-Fan Gao, Mina Stanikic, Eshna Lahr et al. · 0 citations
Review Sep 2026

Abstract A091: Single-cell spatial transcriptomics reveals reprograming molecular hallmarks of PanIN initiation and progression preceding histological changes

Recent studies have identified a high prevalence of low grade pancreatic intraepithelial neoplasia (PanIN) in the pancreata of healthy adults. This study aimed to characterize the transcriptomic landscape of human PanINs at single cell resolution, with the goal of identifying hallmarks of initiation and progressi...

C. Nguyen, Anders W. Ohman, Winston R. Becker et al. · 0 citations
Sep 2026

Abstract A140: Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...

A. Habowski, Fatim M. Kouassi, James A. Rouse et al. · 0 citations
Open access Aug 2026

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer

MULTIPL demonstrated robust prognostic performance in external validation, identified a subgroup enriched for benefit from GNP, and enabled discovery and validation of prognostic biomarkers in metastatic PDAC, underscoring the value of the PASS-01 Challenge.

W. Quan, D. Henault, A. Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.